The abstract is read at the publisher; the summary is JClub's.
Among 38 NCI-funded cancer pragmatic-trial grants (Sep 2009–Dec 2023), nearly 60% used investigator-initiated R01 mechanisms, with about half funded in 2021–2023.
- Why it matters: The field needs clearer characterization of how cancer-related pragmatic trials are being proposed, balancing rigor with real-world generalizability.
- What they did: Investigators performed a portfolio analysis of U.S. National Cancer Institute grants, using a refined codebook and two independent reviewers to code descriptive features of proposed pragmatic trials.
- The result: Most proposals planned community and academic medical center settings, included diverse racial/ethnic participants and both sexes, but only 11 grants referenced key pragmatic-trial design articles or tools.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.